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Background: Selective serotonin reuptake inhibitors (SSRIs) and exposure with response prevention for treatment of obsessive-
compulsive disorder (OCD) have demonstrated empirical support; however, a substantial number of patients remain with clinically 
significant OCD symptoms after such treatments. 
Objectives: The aim of this study was to compare the effectiveness of acceptance and commitment therapy (ACT), selective serotonin 
reuptake inhibitors (SSRIs) and combination of ACT and SSRIs in the treatment of adults with obsessive-compulsive disorder (OCD).
Patients and Methods: Thirty-two outpatients meeting Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text 
Revision criteria for OCD were randomly assigned to one of the three treatment conditions: ACT, SSRIs and combined treatment. The Yale-
Brown Obsessive-Compulsive Scale and Acceptance and Action Questionnaire were administered at pre-treatment and post-treatment. 
Twenty-seven patients completed the study. Data was analyzed using one-way analysis of variance (ANOVA) and one-way analysis of 
covariance (ANCOVA), clinically significant change (CSC) and complete remission status.
Results: ANCOVA revealed that patients treated with ACT and combined treatment experienced a significantly greater improvement 
in obsessive-compulsive (OC) symptoms and experiential avoidance (EA) at post-treatment compared to those treated with SSRIs alone. 
However, there were no significant differences between ACT and combined treatment on OC symptoms and EA. CSC and complete 
remission status results showed that unlike SSRI, ACT and combined treatment led to more improvement in OC symptoms.
Conclusions: ACT and combined treatment are more effective than SSRIs alone in treating OC symptoms and EA. However, it appears that 
adding SSRIs to ACT does not increase the effectiveness of ACT in the treatment of adults with OCD in the short-term.
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1. Background
Selective serotonin reuptake inhibitors (SSRIs) and ex-
posure with response prevention for treatment of ob-
sessive-compulsive disorder (OCD) have demonstrated 
empirical support; however, a substantial number of pa-
tients remain with clinically significant OCD symptoms 
after these treatments (1-6). In recent years, one of the 
promising novel treatment strategies developed to im-
prove the efficacy of treatment for patients with OCD is 
acceptance and commitment therapy (ACT) (7, 8). ACT is 
a third-wave behavior therapy, which specifically focuses 
on decreasing experiential avoidance (EA), increasing ac-
tivity in the chosen valued life direction and increasing 
psychological flexibility. The goal of ACT is not symptom 
reduction per se, but helping patients to accept aversive 
inner experiences (e.g. thoughts, images, emotions and 
bodily sensations) in the service of engaging in values-
guided behavior (9).
EA is defined as unwillingness to remain in contact or 
experience aversive private thoughts or experiences to 
avoid or escape from these experiences (7). EA has been 
suggested to play an important role in the development 
and maintenance of OCD (10). EA has been hypothesized 
to manifest as compulsions in OCD (10). In EA perspec-
tive, patients with OCD engage in compulsions to control 
or reduce their unwanted obsessional thoughts, because 
they want to reduce negative affect associated with them 
(10). In support of this perspective, correlational studies 
have found that high levels of EA were positively associ-
ated with high levels obsessive-compulsive (OC) symp-
toms (11-13). In treating OCD, ACT targets EA and cognitive 
fusion through “defusion” and acceptance techniques. 
ACT teaches patients to create a new relationship with 
obsessive thoughts and anxious emotions, for example, 
helping patients notice that a thought is just thought 
and anxiety is an emotion to be felt. ACT also helps pa-
tients commit to act in the service of their valued life 
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goals rather than spending large amounts of time try-
ing to decrease the obsession or avoid anxious feelings. 
ACT helps patients to accept their obsessional thoughts 
and negative feelings and commit to acting in service of 
their valued life directions whether obsessions were oc-
curring. Thus, these constructs would increase psycho-
logical flexibility, which is the ability to act inconsistent 
with patient’s meaningful life directions regardless of 
unpleasant inner experiences (14, 15).
ACT has demonstrated large and clinically significant 
improvements in OCD symptoms in adults (14-17) and ado-
lescent (18). However, according to the best of our knowl-
edge, there are no randomized controlled studies directly 
comparing the relative effectiveness of ACT with SSRIs and 
combination of ACT and SSRIs in the treatment of OCD.
2. Objectives
Therefore, the aim of this study was to compare ACT 
with SSRIs and combination of ACT and SSRIs in improve-
ment of OC symptoms and EA.
3. Materials and Methods
In an experimental design using convenience sam-
pling, adults with OCD were recruited from outpatients 
of clinics in Tehran, Iran, from February 2012 to March 
2013. The study was approved by the Ethics Commit-
tee of Tehran University of Medical Sciences. A written 
informed consent was obtained from patients and re-
ceived complete descriptions regarding the study pro-
cedures. Inclusion criteria for the sample were: a) a pri-
mary diagnosis of OCD according to the Diagnostic and 
Statistical Manual of Mental Disorders, Fourth Edition, 
Text Revision (DSM-IV-TR) (19); b) age between 18 and 
50 years; and c) OC symptoms duration of at least one 
year. Patients were excluded from the study if they: a) 
had a current or past psychotic disorder; b) had suicidal 
tendencies; c) had a medical illness; d) had a substance 
abuse disorder; e) had a personality disorder and f) had 
been treated with either pharmacotherapy or psycho-
therapy in the last one month. Forty-four patients were 
referred for treatment, of which 40 met the DSM-IV-TR 
criteria for OCD. They were interviewed by a structured 
clinical interview for DSM-IV axis I disorders, patient edi-
tion (SCID-I/P version 2) (20) and a structured clinical in-
terview for DSM-IV axis II disorders (SCID-II) (21) to verify 
the diagnosis by an independent evaluator (PhD level 
clinical psychologist). Two patients with bipolar disor-
der, two patients with psychotic disorder, one patient 
with avoidant personality disorder, two patients with 
OC personality disorder and one patient with borderline 
personality disorder were excluded from the study. In 
all, 32 patients fitted the inclusion/exclusion criteria and 
were randomly assigned to receive ACT (n = 10), SSRIs (n = 
11) or combination of ACT and SSRIs (n = 11). Five patients 
did not complete the study. Three patients dropped out 
the drug group; one because of not tolerating adverse 
effects of sertraline and two for irregular use of fluox-
etine. One patient abandoned the ACT group for needing 
SSRI during the treatment phase. One patient dropped 
out of the combination group for unknown reasons.
The mean age of the final sample (n = 27) was 26.96 ± 6.83 
years; 55.6% (n = 15) of the patients were men and 44.4% (n 
= 12) women. Duration of OC symptoms ranged between 1 
and 16 years. The Yale-Brown Obsessive-Compulsive Scale 
(Y-BOCS) total and Acceptance and Action Questionnaire 
(AAQ) scores (mean ± standard deviation) for the sample 
were 24.40 ± 3.07 and 36.20 ± 6.08, respectively. All patients 
met the criteria for OCD as their primary diagnosis with 
33.3% receiving one additional diagnosis. The frequency of 
comorbidities in each treatment condition was as follows; 
major depressive disorder and dysthymia, two ACT, two 
SSRIs, two ACT plus SSRIs; anxiety disorders, one ACT, one 
SSRI, one ACT plus SSRIs. OCD subtypes for the sample were 
washing, checking, ordering, religious/sexual/aggressive 
thoughts and hoarding.
ACT was based on an ACT manual for OCD developed by 
Twohig (14). A PhD clinical psychologist (the first author) 
provided ACT under the supervision of an experienced 
clinical psychologist in treating OCD. The ACT program in-
cluded evaluating patient’s obsessions and compulsions 
(session 1); The “Man in the hole” metaphor was used to il-
lustrate how patient’s efforts to regulate obsessions are inef-
fective (session 2); The “Tow scales” metaphor was used to 
illustrate possible benefits of acceptance of obsessions and 
anxiety rather than attempting to control or reduce them 
(sessions 3 and 4); using defusion, contact with present or 
mindfulness, and self as context exercises (sessions 5 and 
6); recognize his values; and preventing relapse (sessions 
7 and 8). Patients in drug group received a different SSRI 
(sertraline = 50 - 200 mg/d; fluoxetine = 20 - 80 mg/d) for 
10 weeks, which was monitored by two psychiatrists. The 
combination group received both ACT and a different SSRI 
(sertraline = 50 - 200 mg/d; fluoxetine = 20 - 80 mg/d) for 10 
weeks. Studies showed equivalent efficacy for different SS-
RIs in OCD (2). In this study, we did not compare the efficacy 
of sertraline with fluoxetine on each outcome measure at 
the end of treatment.
SCID-I/P and SCID-II are widely used as gold standard in-
struments for diagnosing axis I and axis II disorders (22). All 
participants were initially assessed using the SCID-I/P and 
SCID-II. Clinical symptoms were assessed using the Y-BOCS 
(23, 24), AAQ (25) at the beginning and end of treatment.
Y-BOCS is a 10-item clinician administered scale used for 
the assessment of severity of OC symptoms. It has good psy-
chometric properties and has shown excellent treatment 
sensitivity (23, 24, 26, 27). AAQ is a 9-item self-report scale, 
which assesses EA. Each item is rated on a 7-point scale with 
higher scores indicating greater EA (range: 7 - 63). It has 
demonstrated good internal consistency (α = 0.70) and 
test-retest reliability over a 4-month interval (rs = 0.64) (24). 
The reliability and validity of the Iranian version of the Y-
BOCS (28), AAQ (29), SCID-I/P and SCID-II (30) have been eval-
uated and shown to be as good as their original versions.
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The criteria for clinically significant change (CSC) con-
sidered a Y-BOCS total score reduction of eight scores or 
more from pre-treatment to post-treatment and a final Y-
BOCS total score ≤ 14. Patients who achieved CSC were de-
fined as recovered. Patients were classified as improved if 
they achieved reliable change that is eight score or more, 
but scoring above 14 on Y-BOCS total. Patients who did 
not achieve reliable change on the Y-BOCS were defined 
as unchanged (6). Full remission was defined as post-
treatment Y-BOCS total score ≤ 8 (31).
Group differences were evaluated using chi-square, one-
way analysis of variance (ANOVA) and one-way analysis of 
covariance (ANCOVA) statistical procedures on each of the 
outcome measures using SPSS for Windows (version 16.0, 
SPSS Inc., Chicago, IL, USA) statistical package.
4. Results
Using ANOVA and chi-square test, no significant dif-
ference was found between the groups regarding de-
mographic characteristics and pre-treatment measures 
(Tables 1 and 2).4.1. CSC
Patients achieving CSC at post-treatment were 44.4%, 
40.0% and 12.5% for ACT, combined and SSRIs groups, re-
spectively. Two patients (22.2%) in ACT and two patients 
(20.0%) in combined group and two patients (25.0%) in SS-
RIs group met the criteria for reliability improved. Three 
patients (33.3%) in ACT, four patients (40.0%) in combined 
and five patients (62.5%) in SSRIs groups were classified as 
unchanged.
Table 1. Demographic Characteristics, Analysis of Variance a,b





5/4 4/4 6/4 χ2 = 0.18
Proportion 
single/married
4/5 4/4 5/5 χ2 = 0.08
Age, y 25.89 ± 5.58 27.13 ±4.48 27.80 ±9.46 F = 0.17
Education, y 14.33 ±1.32 13.12 ± 2.29 14.20 ± 1.81 F = 1.10
OCD duration, y 5.22 ± 1.85 5.63 ± 2.67 6.20 ± 4.44 F = 0.22
a  Abbreviations: ACT, Acceptance and commitment therapy; OCD, 
Obsessive-compulsive disorder; and SSRIs, Selective serotonin reuptake 
inhibitors.
b  Data are presented as Mean ± SD, and all P > 0.001.
Table 2. Pre-Treatment Outcome Measures, Analysis of Vari-
ance a,b
Measure Group F Statistic
ACT SSRIs Combined
Y-BOCS 23.86 ± 2.57 25.63 ± 2.44 24.10 ± 3.69 0.76
AAQ 34.89 ± 6.71 38.25 ± 5.54 35.80 ± 5.88 0.68
a  Abbreviations: AAQ, Acceptance and Action Questionnaire; ACT, 
Acceptance and commitment therapy; SSRIs, Selective serotonin reuptake 
inhibitors; and Y-BOCS, Yale-Brown Obsessive-Compulsive Scale.
b  Data are presented as Mean ± SD, and all P > 0.001.
4.2. Full Remission
Regarding the criteria for OC symptoms full remission 
(Y-BOCS score ≤ 8), two patients (22.2%) in ACT and two 
patients (20.0%) in combined group achieved this im-
provement level, but none of the patients in SSRIs group 
had full remission.
4.3. ANCOVA Results
 Table 3 displays the mean scores, standard deviation 
and ANCOVA results on each outcome measure at the 
end of treatment. The assumptions of homogeneity 
of variance and homogeneity of regression were met 
for each of the comparisons. ANCOVA results revealed 
significant differences between the groups on Y-BOCS 
and AAQ. Pair-wise post-hoc comparisons of the means 
of the groups showed significant differences between 
ACT and SSRIs as well as between combined treatment 
and SSRIs on the Y-BOCS and AAQ at post-treatment. 
However, there were no significant differences be-
tween ACT and combined treatment on the measures. 
Effect sizes using Cohen’s d (difference between ad-
justed means divided by the pooled standard deviation 
(32) was calculated to evaluate the size of differences 
between the treatment groups. Large effect sizes were 
found for differences between the ACT group and the 
SSRI group as well as between the combined group and 
the SSRI group on the Y-BOCS and AAQ. However, there 
were no significant differences between ACT and com-
bined groups on OC symptoms and EA at post-treat-
ment (Table 4).
Table 3. Post-Treatment Outcome Measures, Analysis of Cova-
riance (Using the Pre-Treatment Scores as the Covariate) a,b
Measure Group F Statistic
ACT SSRIs Combined
Y-BOCS 14.00 ± 4.55 19.88 ± 3.68 13.80 ± 3.85 05.03
AAQ 23.33 ± 5.95 33.50 ± 6.37 23.20 ± 5.32 12.46
a  Abbreviations: AAQ, Acceptance and Action Questionnaire; ACT, 
Acceptance and commitment therapy; SSRIs, Selective serotonin reuptake 
inhibitors; and Y-BOCS, Yale-Brown Obsessive-Compulsive Scale.
b  Data are presented as Mean ± SD, and P < 0.05.
Table 4. Effect Sizes for Pairwise Post-Hoc Comparisons a,b
Measure ACT vs. SSRIs ACT vs. Combined Combined 
vs. SSRIs
Y-BOCS 1.14 c 0.07 1.28 c
AAQ 1.18 c 0.14 1.35 c
a  Abbreviations: AAQ, Acceptance and Action Questionnaire; ACT, 
Acceptance and commitment therapy; SSRIs, Selective serotonin 
reuptake inhibitors; and Y-BOCS, Yale-Brown Obsessive-Compulsive Scale.
b  d = Cohen’s effect size (0.2 = small effect, 0.5 = medium effect, 0.8 = 
large effect).
c  P < 0.001.
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5. Discussion
All three treatments were effective in reducing total 
scores in the Y-BOCS and AAQ at post-treatment. Neverthe-
less, ACT and combined treatment presented significant-
ly greater improvements in severity of OC symptoms and 
EA and a higher rate of complete remission of OC symp-
toms than those resulting from SSRIs use. Furthermore, 
ACT and combined treatment produced greater rates of 
recovery in OC symptoms compared to SSRIs alone.
Regarding OC symptoms improvement, our results were 
similar to those found in previous studies with ACT (14-
18) and SSRIs (1, 2). The rate of reduction in the Y-BOCS in 
the study of Twohig et al. (15), was 47.3% at post-treatment, 
which is virtually the same as 41.3% reduction at the end of 
ACT observed in the current study. A possible explanation 
for the effectiveness of ACT may be the fact that reductions 
in EA and cognitive fusion produce greater psychological 
flexibility. ACT aimed at helping patients to accept their 
obsessional thoughts and negative feelings and commit 
to acting in service of their valued life goals regardless of 
obsessions were occurring. Increasing psychological flex-
ibility and values-based action in the presence of obses-
sional thoughts and negative emotions could be a core 
process of change in OC symptoms (15). In support of this 
perspective, evidence (14-18) show that reduction in OC 
symptoms is due to specific processes used in ACT (i.e. ac-
ceptance and cognitive defusion). ACT processes (e.g. re-
ductions in EA) changed prior to changes in OCD severity. 
In the present study, EA decreased in ACT and combined 
treatment groups, without significant difference between 
the groups. These results are inconsistent with studies of 
Twohig (14), Twohig et al. (15, 16) and Armstrong (18), which 
demonstrated reductions in EA in patients with OCD fol-
lowing ACT. From an ACT perspective, increasing one’s 
willingness to experience obsessional thoughts and nega-
tive feelings and not engage in behaviors to decrease them 
produces reductions in EA and compulsions (15).
The finding that ACT is more effective in improving OC 
symptoms than SSRIs is consistent with previous find-
ings by Foa et al. (33), Sousa et al. (31), Abramowitz et al. 
(34) and Shareh et al. (35) who found the superiority of 
psychotherapy over anti-obsessive drugs alone in the 
treatment of adults with OCD. Similarly, Foa et al. (33), 
Shareh et al. (35) and Giasuddin et al. (36) observed that 
the combination of psychotherapy and pharmacothera-
py reached better results than pharmacotherapy alone.
Eddy et al. (3) by reviewing 18 randomized controlled tri-
als found that the combination treatment is more effec-
tive in reducing OC symptoms than either psychotherapy 
or medication alone. However, in the present study, the 
combined treatment was only more effective in reducing 
total scores in the Y-BOCS than medication alone. In this 
study, no significant differences were found between ACT 
and combined treatment regarding the OC symptoms im-
provement. These findings support the results of two stud-
ies (37, 38), which found no advantages of combining med-
ication and psychotherapy compared to psychotherapy 
alone in treating patients with OCD, although, unlike the 
present study, these studies found no significant differenc-
es between combined treatment and medication alone.
The results of the present study demonstrated that 
combining SSRIs with ACT does not increase the effec-
tiveness of ACT in improving OC symptoms and EA in pa-
tients with OCD in short-time. Moreover, patients treated 
with ACT and combined treatment experienced further 
improvement in OC symptoms and EA at post-treatment 
compared to those treated with SSRIs alone.
This study had several limitations. The sample size was 
small, and thus, these findings should be considered pre-
liminary until replicated in larger sample sizes. Further 
researches are necessary to examine whether our results 
are applicable to patients with OCD and other comorbid 
conditions excluded from this study. The present study 
did not have a follow-up assessment. Therefore, future 
research is needed to evaluate long-term effects of all 
three mentioned treatments for OCD. It is recommended 
to perform further studies to compare the effectiveness 
of ACT with other empirically supported treatments and 
combination of these treatments with SSRIs for OCD. De-
spite these limitations, our results provided supporting 
evidence for effectiveness of ACT in helping patients with 
OCD to experience significant improvements in EA and 
OC symptoms, as well highlighted the importance and 
need for additional studies in this area.
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